Mimedx Group Inc (MDXG) 5.49 $MDXG
MiMedx Announces $10 Million Stock Repurchase Program
PR Newswire - Mon May 12, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its Board of Directors has approved a stock repurchase program. Under the terms of the program, the Company may repurchase up to $10 million of its common stock from time to time through December 31, 2014. The timing and amount of repurchases, if any, will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.
Two New MiMedx Scientific Studies Published In Peer-Reviewed Journals
PR Newswire - Tue May 06, 3:44PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that two of its peer-reviewed scientific studies have been published in the scientific literature.
MiMedx Issued Four New U.S. Patents For Placental Tissue Allografts
PR Newswire - Tue Apr 29, 3:41PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its receipt of four newly issued patents related to the Company's tissue allografts derived from the placenta.
MTF stands behind amnion products; will fight patent infringement charge
PR Newswire - Mon Apr 28, 9:00AM CDT
The Musculoskeletal Transplant Foundation (MTF) has been notified that on April 21, 2014, MiMedx Group, Inc. (MiMedx) filed a complaint in the United States District Court for the Northern District of Georgia, naming MTF, together with Liventa Bioscience, Inc. and Medline Industries Inc., as defendants. The complaint alleges patent infringement by MTF of four MiMedx patents. MTF does not believe it infringes any of the patents and is prepared to defend itself, which includes taking such appropriate counter-measures against MiMedx as are necessary and warranted to protect its amnion products and customers. MTF intends to vigorously defend its rights and ensure that MiMedx does not unlawfully interfere with any of its business partners or markets. MTF has the resources and stamina to take the two, three or even four years that may be needed to prove its position in the courts.
MiMedx Announces Record Quarterly Results
PR Newswire - Fri Apr 25, 6:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended March 31, 2014.
Liventa Bioscience Responds To Lawsuit
PR Newswire - Wed Apr 23, 10:16AM CDT
Liventa Bioscience, (formerly AFCell Medical), one of the leading innovators of allograft implants from human amniotic membrane in the United States, has received notice that MiMedx Group, Inc. (MDXG), filed a patent infringement lawsuit against it, its partner in the wound care market, Medline and Liventa's processing partner, Musculoskeletal Transplant Foundation, Inc. (MTF).
MiMedx at SAWC Spring 2014: Multiple Studies And Clinical Experience Demonstrate Clinical And Cost Effectiveness Of EpiFix Allograft For Treatment Of Hard-to-Heal Wounds
PR Newswire - Wed Apr 23, 10:12AM CDT
EpiFix®, dehydrated human amnion/chorion membrane (dHACM) allografts, were shown to be clinically and cost effective in the treatment of multiple hard-to-treat wounds like diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers (PUs), according to data and case experiences being presented at the Spring Symposium on Advanced Wound Care, the leading national wound healing conference now in its 27th year. The symposium begins today, April 23, 2014, and concludes on April 27, 2014.
MiMedx Files Lawsuit Against Liventa, Medline, And Musculoskeletal Transplant Foundation
PR Newswire - Tue Apr 22, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has filed a patent infringement lawsuit against Liventa Bioscience, Inc. ("Liventa"
, Medline Industries, Inc. ("Medline" and Musculoskeletal Transplant Foundation, Inc. ("MTF" for permanent injunctive relief and unspecified damages. In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients and in some cases, prospective investors. The suit was filed in the United States District Court for the Northern District of Georgia.
MiMedx Sponsors Scott Rigsby, Double-Amputee
PR Newswire - Mon Apr 21, 6:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its sponsorship of Scott Rigsby, a double-amputee athlete. As part of the relationship, Rigsby will be taking his "inspire, inform, enable" message to Boston as he returns to run the 2014 Boston Marathon on April 21.
Biotech Stocks Coverage -- Research on Seattle Genetics, Theravance, Neurocrine Biosciences, and MiMedx
PR Newswire - Thu Apr 10, 11:30AM CDT
On Wednesday, April 09, 2014, the NASDAQ Composite ended at 4,183.90, up 1.72%, the Dow Jones Industrial Average advanced 1.11% to 16,437.18, and the S&P 500 closed at 1,872.18, up 1.09%. The gains were broad based as eight out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 673.27, up 2.11%, and the same has advanced 2.86% in the last three months. Investor-Edge has initiated coverage on the following equities: Seattle Genetics Inc. (NASDAQ: SGEN), Theravance Inc. (NASDAQ: THRX), Neurocrine Biosciences Inc. (NASDAQ: NBIX) and MiMedx Group Inc. (NASDAQ: MDXG). Free technical research on SGEN, THRX, NBIX and MDXG can be downloaded upon signing up at:
MiMedx First Quarter Revenue Exceeded Upper End Of Guidance
PR Newswire - Mon Apr 07, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its first quarter of 2014 revenue slightly exceeded the upper end of its previously announced guidance. The Company also announced its guidance for the second quarter of 2014.
MiMedx to Present at the 13th Annual Needham Healthcare Conference
PR Newswire - Fri Mar 28, 1:22PM CDT
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 13th Annual Needham Healthcare Conference in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Tuesday, April 8th at 3:00 p.m. EDT, at the Westin NY Grand Central Hotel. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MiMedx Schedules Shareholder Call To Update Progress Of FDA Discussions, Reimbursement Successes And Recent Short-Selling Initiatives
PR Newswire - Mon Mar 24, 7:34AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today it will host a shareholder call tomorrow, Tuesday, March 25, 2014 at 11:00 AM Eastern Time to update shareholders on the positive progress of its discussions with the Food and Drug Administration ("FDA" regarding the Company's micronized allograft. During the call, the Company also plans to provide updates on its progress with wound care reimbursement, its sales force expansion, as well as its reaction to the misinformation in certain recent short-selling related blogs.
MiMedx to Present at 2nd Annual Regen Med Investor Day
PR Newswire - Mon Mar 17, 10:31AM CDT
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 2nd Annual Regen Med Investor Day in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Wednesday, March 26th, 3:45 p.m. EDT, at the Metropolitan Club. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MiMedx EpiFix® Allograft Receives Medicare Coverage From The Final Medicare Contractor
PR Newswire - Thu Mar 13, 1:11PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Medicare contractor, First Coast Service Options, Inc. ("FCSO" , has confirmed that the Company's wound care allograft, EpiFix®, has been approved for coverage when applied in the hospital outpatient and ambulatory surgery center settings.
MiMedx To Present At 2014 Canaccord Genuity Musculoskeletal Conference
PR Newswire - Tue Mar 04, 3:52PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 2014 Canaccord|Genuity Musculoskeletal Conference in New Orleans, Louisiana. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Tuesday, March 11th at 10:00am CDT/11:00am EDT, at the Sheraton New Orleans. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MiMedx Announces Record 2013 Results
PR Newswire - Wed Feb 26, 6:30AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the year ended December 31, 2013.
MiMedx Sponsored Osteoarthritis Study Using PURION® Processed Amniotic Tissue Published In Arthritis Research & Therapy
PR Newswire - Tue Feb 25, 7:10PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today a MiMedx-sponsored study from Georgia Institute of Technology has been published in Arthritis Research & Therapy. The article, titled "Intra-articular injection of micronized dehydrated human amnion/chorion membrane attenuates osteoarthritis development" was authored by Nick Willett, Tanushree Thote, Angela Lin, Shamus Moran, Yazdan Raji, Sanjay Sridaran, Hazel Stevens and Robert Guldberg. The electronic publication of the study is available at http://arthritis-research.com/content/16/1/R47.
Second MiMedx EpiFix® Randomized Comparative Study Published In International Wound Journal Shows 92.5% Healing Rate Over 12 Weeks
PR Newswire - Tue Feb 25, 6:07PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its study "A prospective, randomized comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers" has been published electronically in the International Wound Journal. The study manuscript was authored by Charles M. Zelen, DPM, FACFAS; Thomas E. Serena MD, FACS; and Robert J. Snyder, DPM, MSc.
MiMedx EpiFix® Allograft Awarded Coverage by HCSC
PR Newswire - Wed Feb 12, 7:30AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Health Care Services Corporation (HCSC) has confirmed that the Company's EpiFix® allograft has been awarded reimbursement coverage. HCSC is the largest customer-owned health insurance company in the United States with nearly 14 million members.
MiMedx Announces $10 Million Stock Repurchase Program
PR Newswire - Mon May 12, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its Board of Directors has approved a stock repurchase program. Under the terms of the program, the Company may repurchase up to $10 million of its common stock from time to time through December 31, 2014. The timing and amount of repurchases, if any, will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.
Two New MiMedx Scientific Studies Published In Peer-Reviewed Journals
PR Newswire - Tue May 06, 3:44PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that two of its peer-reviewed scientific studies have been published in the scientific literature.
MiMedx Issued Four New U.S. Patents For Placental Tissue Allografts
PR Newswire - Tue Apr 29, 3:41PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its receipt of four newly issued patents related to the Company's tissue allografts derived from the placenta.
MTF stands behind amnion products; will fight patent infringement charge
PR Newswire - Mon Apr 28, 9:00AM CDT
The Musculoskeletal Transplant Foundation (MTF) has been notified that on April 21, 2014, MiMedx Group, Inc. (MiMedx) filed a complaint in the United States District Court for the Northern District of Georgia, naming MTF, together with Liventa Bioscience, Inc. and Medline Industries Inc., as defendants. The complaint alleges patent infringement by MTF of four MiMedx patents. MTF does not believe it infringes any of the patents and is prepared to defend itself, which includes taking such appropriate counter-measures against MiMedx as are necessary and warranted to protect its amnion products and customers. MTF intends to vigorously defend its rights and ensure that MiMedx does not unlawfully interfere with any of its business partners or markets. MTF has the resources and stamina to take the two, three or even four years that may be needed to prove its position in the courts.
MiMedx Announces Record Quarterly Results
PR Newswire - Fri Apr 25, 6:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended March 31, 2014.
Liventa Bioscience Responds To Lawsuit
PR Newswire - Wed Apr 23, 10:16AM CDT
Liventa Bioscience, (formerly AFCell Medical), one of the leading innovators of allograft implants from human amniotic membrane in the United States, has received notice that MiMedx Group, Inc. (MDXG), filed a patent infringement lawsuit against it, its partner in the wound care market, Medline and Liventa's processing partner, Musculoskeletal Transplant Foundation, Inc. (MTF).
MiMedx at SAWC Spring 2014: Multiple Studies And Clinical Experience Demonstrate Clinical And Cost Effectiveness Of EpiFix Allograft For Treatment Of Hard-to-Heal Wounds
PR Newswire - Wed Apr 23, 10:12AM CDT
EpiFix®, dehydrated human amnion/chorion membrane (dHACM) allografts, were shown to be clinically and cost effective in the treatment of multiple hard-to-treat wounds like diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers (PUs), according to data and case experiences being presented at the Spring Symposium on Advanced Wound Care, the leading national wound healing conference now in its 27th year. The symposium begins today, April 23, 2014, and concludes on April 27, 2014.
MiMedx Files Lawsuit Against Liventa, Medline, And Musculoskeletal Transplant Foundation
PR Newswire - Tue Apr 22, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has filed a patent infringement lawsuit against Liventa Bioscience, Inc. ("Liventa"
, Medline Industries, Inc. ("Medline" and Musculoskeletal Transplant Foundation, Inc. ("MTF" for permanent injunctive relief and unspecified damages. In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients and in some cases, prospective investors. The suit was filed in the United States District Court for the Northern District of Georgia. MiMedx Sponsors Scott Rigsby, Double-Amputee
PR Newswire - Mon Apr 21, 6:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its sponsorship of Scott Rigsby, a double-amputee athlete. As part of the relationship, Rigsby will be taking his "inspire, inform, enable" message to Boston as he returns to run the 2014 Boston Marathon on April 21.
Biotech Stocks Coverage -- Research on Seattle Genetics, Theravance, Neurocrine Biosciences, and MiMedx
PR Newswire - Thu Apr 10, 11:30AM CDT
On Wednesday, April 09, 2014, the NASDAQ Composite ended at 4,183.90, up 1.72%, the Dow Jones Industrial Average advanced 1.11% to 16,437.18, and the S&P 500 closed at 1,872.18, up 1.09%. The gains were broad based as eight out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 673.27, up 2.11%, and the same has advanced 2.86% in the last three months. Investor-Edge has initiated coverage on the following equities: Seattle Genetics Inc. (NASDAQ: SGEN), Theravance Inc. (NASDAQ: THRX), Neurocrine Biosciences Inc. (NASDAQ: NBIX) and MiMedx Group Inc. (NASDAQ: MDXG). Free technical research on SGEN, THRX, NBIX and MDXG can be downloaded upon signing up at:
MiMedx First Quarter Revenue Exceeded Upper End Of Guidance
PR Newswire - Mon Apr 07, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its first quarter of 2014 revenue slightly exceeded the upper end of its previously announced guidance. The Company also announced its guidance for the second quarter of 2014.
MiMedx to Present at the 13th Annual Needham Healthcare Conference
PR Newswire - Fri Mar 28, 1:22PM CDT
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 13th Annual Needham Healthcare Conference in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Tuesday, April 8th at 3:00 p.m. EDT, at the Westin NY Grand Central Hotel. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MiMedx Schedules Shareholder Call To Update Progress Of FDA Discussions, Reimbursement Successes And Recent Short-Selling Initiatives
PR Newswire - Mon Mar 24, 7:34AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today it will host a shareholder call tomorrow, Tuesday, March 25, 2014 at 11:00 AM Eastern Time to update shareholders on the positive progress of its discussions with the Food and Drug Administration ("FDA"
regarding the Company's micronized allograft. During the call, the Company also plans to provide updates on its progress with wound care reimbursement, its sales force expansion, as well as its reaction to the misinformation in certain recent short-selling related blogs. MiMedx to Present at 2nd Annual Regen Med Investor Day
PR Newswire - Mon Mar 17, 10:31AM CDT
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 2nd Annual Regen Med Investor Day in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Wednesday, March 26th, 3:45 p.m. EDT, at the Metropolitan Club. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MiMedx EpiFix® Allograft Receives Medicare Coverage From The Final Medicare Contractor
PR Newswire - Thu Mar 13, 1:11PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Medicare contractor, First Coast Service Options, Inc. ("FCSO"
, has confirmed that the Company's wound care allograft, EpiFix®, has been approved for coverage when applied in the hospital outpatient and ambulatory surgery center settings. MiMedx To Present At 2014 Canaccord Genuity Musculoskeletal Conference
PR Newswire - Tue Mar 04, 3:52PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 2014 Canaccord|Genuity Musculoskeletal Conference in New Orleans, Louisiana. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Tuesday, March 11th at 10:00am CDT/11:00am EDT, at the Sheraton New Orleans. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MiMedx Announces Record 2013 Results
PR Newswire - Wed Feb 26, 6:30AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the year ended December 31, 2013.
MiMedx Sponsored Osteoarthritis Study Using PURION® Processed Amniotic Tissue Published In Arthritis Research & Therapy
PR Newswire - Tue Feb 25, 7:10PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today a MiMedx-sponsored study from Georgia Institute of Technology has been published in Arthritis Research & Therapy. The article, titled "Intra-articular injection of micronized dehydrated human amnion/chorion membrane attenuates osteoarthritis development" was authored by Nick Willett, Tanushree Thote, Angela Lin, Shamus Moran, Yazdan Raji, Sanjay Sridaran, Hazel Stevens and Robert Guldberg. The electronic publication of the study is available at http://arthritis-research.com/content/16/1/R47.
Second MiMedx EpiFix® Randomized Comparative Study Published In International Wound Journal Shows 92.5% Healing Rate Over 12 Weeks
PR Newswire - Tue Feb 25, 6:07PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its study "A prospective, randomized comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers" has been published electronically in the International Wound Journal. The study manuscript was authored by Charles M. Zelen, DPM, FACFAS; Thomas E. Serena MD, FACS; and Robert J. Snyder, DPM, MSc.
MiMedx EpiFix® Allograft Awarded Coverage by HCSC
PR Newswire - Wed Feb 12, 7:30AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Health Care Services Corporation (HCSC) has confirmed that the Company's EpiFix® allograft has been awarded reimbursement coverage. HCSC is the largest customer-owned health insurance company in the United States with nearly 14 million members.
